BMS, Mi­rati fund new Stand Up To Can­cer re­search teams, adding to list of phar­ma part­ner­ships

Stand Up To Can­cer is well-known for its celebri­ty con­nec­tions and gala fundrais­ing events, but in phar­ma and biotech, it’s al­so known as a re­search part­ner. Its two re­cent­ly added teams part­ner with Bris­tol My­ers Squibb on lung can­cer dis­par­i­ties and Mi­rati Ther­a­peu­tics on KRAS can­cers.

The new ad­di­tions aug­ment Stand Up To Can­cer’s phar­ma part­ner­ships, which in­clude 13 teams in its Cat­a­lyst pro­gram. The Cat­a­lyst pro­gram launched in 2016, spon­sored ini­tial­ly by BMS, Mer­ck and Roche’s Genen­tech, to pair in­dus­try fund­ing and ma­te­ri­als with sci­en­tif­ic part­ners with the am­bi­tion to ac­cel­er­ate can­cer re­search, de­tec­tion and treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER